Royal London Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Royal London Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$7.21M	Hold	54,763	–	–	0.02%	505
2025 Q4	$7.77M	Buy	54,763 +959	+2%	+$139K	0.02%	486
2025 Q3	$7.55M	Hold	53,804	–	–	0.02%	486
2025 Q2	$6.76M	Sell	53,804 -3,171	-6%	-$364K	0.02%	507
2025 Q1	$6.3M	Buy	56,975 +5,442	+11%	+$689K	0.01%	530
2024 Q4	$7.03M	Hold	51,533	–	–	0.02%	494
2024 Q3	$5.94M	Buy	51,533 +6,060	+13%	+$831K	0.01%	531
2024 Q2	$6.26M	Hold	45,473	–	–	0.02%	497
2024 Q1	$6.27M	Buy	45,473 +13,225	+41%	+$1.81M	0.02%	507
2023 Q4	$4.25M	Hold	32,248	–	–	0.01%	565
2023 Q3	$3.63M	Buy	32,248 +2,370	+8%	+$250K	0.01%	571
2023 Q2	$2.82M	Buy	+29,878	New	+$2.92M	0.01%	597

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Royal London Asset Management's NBIX Position: Q1 2026 in Review

Royal London Asset Management held its Neurocrine Biosciences (NBIX) position steady in Q1 2026 at 54,763 shares worth $7.21M. The position accounts for 0.02% of the portfolio, ranked #505.

Royal London Asset Management first reported a position in NBIX in Q2 2023 and has held it in 12 quarters since. The position peaked at $7.77M in Q4 2025. 696 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

Royal London Asset Management held 54,763 shares of Neurocrine Biosciences worth $7.21M as of Q1 2026.
Royal London Asset Management left its Neurocrine Biosciences share count unchanged in Q1 2026.
Neurocrine Biosciences made up 0.02% of Royal London Asset Management's portfolio in Q1 2026, its #505 holding.
Royal London Asset Management first reported a position in Neurocrine Biosciences in Q2 2023 and has held it in 12 quarters since.
Royal London Asset Management's Neurocrine Biosciences position peaked at $7.77M in Q4 2025.
696 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Royal London Asset Management's 13F filing for Q1 2026, filed 1 May 2026.